Record tools

Copy identifiers or export this single peptide record for a local research note.

PEPDIA-INT-015626

Silver

Vosoritide

Quality

Source DBs

Activities

Source refs

Literature

Patents

Integrated record

Sequence and molecular profile

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

Indexed sequence39 aa

1PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

Length

Molecular weight

Formula

Structure type

Cyclic

Synthesis

Chirality

Family

Gene

Residue composition

Physicochemical profile

Hydrophobic10

Membrane affinity proxy

Polar8

Solubility proxy

Charged11

Net charge proxy +7

Aromatic3

Binding interaction proxy

Versioned scientific descriptors

Physicochemical properties and standard representations

partial sequence only structural context

Reported properties

Legacy compatibility fields are materialized from the versioned PepDiana computed release; no separate source-reported property is available.

Computed properties

physchem-20260620

Molecular weight

4104.7409 Da

Molecular formula

Not calculated

Theoretical pI

9.9303

Net charge at pH 7

6.0228

GRAVY

-0.7744

Instability index

14.3538

Aromaticity

0.0513

Topological polar surface area

Not calculated

cLogP

Not calculated

Hydrogen-bond donors

Not calculated

Hydrogen-bond acceptors

Not calculated

Rotatable bonds

Not calculated

Method: PepDiana sequence/structure descriptor pipeline

Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6

Calculated: 2026-06-20T11:01:38.358971+00:00

Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200

Sequence representations

representations-20260620 · RDKit 2024.09.6

ProForma 2.0

not generated modification context

Not calculated for this record

HELM 2.0

not generated modification context

Not calculated for this record

Canonical SMILES

not generated modification context

Not calculated for this record

Isomeric SMILES

not generated modification context

Not calculated for this record

Follow-up research

External analysis tools

Run BLASTPSearch similar protein or peptide sequences at NCBI.Search UniProtLook for related UniProtKB entries using the sequence.Search PubMedFind literature context for this peptide record.

Links open third-party resources with the current PepDiana sequence, record name, or chemistry notation as the initial query.

Research workflow

Citation and local history

BibTeX

@misc{PEPDIA-INT-015626,
  title = {Vosoritide},
  author = {{PepDiana Consortium}},
  year = {2026},
  howpublished = {PepDiana Multifunctional Peptide Database},
  url = {http://127.0.0.1:3004/peptides/PEPDIA-INT-015626},
  note = {Accessed from local PepDiana development build}
}

APA-style note

Vosoritide. (2026). PepDiana record PEPDIA-INT-015626. PepDiana Multifunctional Peptide Database. http://127.0.0.1:3004/peptides/PEPDIA-INT-015626

This record is saved to local recent-view history so it can reappear on the peptide browser page.

Integrated source-database annotations

Biological activity (9 records)

Stable record	Activity	Subtype	Value	Target	Assay method	Source
CTPDB_P015626_ACT_peptherdia_0000	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	111peptherdia / linked
CTPDB_P015626_ACT_thpdb_0001	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13821_rec0thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0002	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13822_rec1thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0003	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13823_rec2thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0004	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13824_rec3thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0005	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13825_rec4thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0006	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13826_rec5thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0007	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13827_rec6thpdb / unavailable
CTPDB_P015626_ACT_thpdb_0008	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1438_13828_rec7thpdb / unavailable

Provenance

Source database records (9)

peptherdia

111

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13821_rec0

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13822_rec1

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13823_rec2

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13824_rec3

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13825_rec4

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13826_rec5

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13827_rec6

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

thpdb

Th1438_13828_rec7

Raw sequence

PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

Citation trail

Literature (1 records)

[{"text": "drugbank.com", "url": "https://go.drugbank.com/drugs/DB11928", "markdown": "[drugbank.com](https://go.drugbank.com/drugs/DB11928)"}, {"text": "fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf", "markdown": "[fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf)"}, {"text": "europa.eu", "url": "https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf", "markdown": "[eu

[{"text": "drugbank.com", "url": "https://go.drugbank.com/drugs/DB11928", "markdown": "[drugbank.com](https://go.drugbank.com/drugs/DB11928)"}, {"text": "fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf", "markdown": "[fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf)"}, {"text": "europa.eu", "url": "https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf", "markdown": "[eu

Audit surface

Raw annotations and release metadata

Integrated record last updated: 2026-04-15T00:59:21.345173+00:00

Modification summary

No structured modification annotations are available for this record.

ADMET

{
  "toxicity": [
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Doses of two- to three-fold the recommended daily dose of 15 mcg/kg were administered to patients in clinical trials with no evidence of associated adverse reactions.[L39237] If an overdose is suspect",
      "toxicity_type": "Toxicity"
    }
  ]
}

Source metadata

[
  {
    "source_db": "peptherdia",
    "organism_name": "Unknown"
  },
  {
    "source_db": "thpdb",
    "organism_name": "Unknown"
  }
]

Clinical trials

[
  {
    "status": "Therapeutic",
    "drug_name": "Vosoritide",
    "source_db": "peptherdia",
    "indication": "An analogue of C-type naturietic peptide used to promote bone growth in pediatric patients with achondroplasia.",
    "approval_year": 2021,
    "approval_agency": "EMA - FDA",
    "administration_route": "SC"
  }
]

Approved drug annotations

{
  "status": "Therapeutic",
  "drug_name": "Vosoritide",
  "source_db": "peptherdia",
  "indication": "An analogue of C-type naturietic peptide used to promote bone growth in pediatric patients with achondroplasia.",
  "approval_year": 2021,
  "approval_agency": "EMA - FDA",
  "administration_route": "SC"
}